Drugs / XTX301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05684965 | May 2023 → Sep 2028 expected | neoplasm | Xilio Development, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XTX301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05684965 ↗ |
| Modality | Protein / enzyme biologic | “XTX301, a tumor-activated interleukin-12” NCT05684965 ↗ |